Drug Profile
Research programme: autoimmune disorders therapy - Trillium Therapeutics Inc
Alternative Names: Anti-CD32a monoclonal antibody; TTI-314Latest Information Update: 29 Nov 2021
Price :
$50
*
At a glance
- Originator Arthron
- Developer Trillium Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Fc gamma receptor IIA antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Idiopathic thrombocytopenic purpura; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 17 Nov 2021 Trillium Therapeutics Inc has been acquired by Pfizer
- 12 Feb 2013 Discontinued - Preclinical for Autoimmune disorders in Canada (Parenteral)
- 12 Feb 2013 Discontinued - Preclinical for Idiopathic thrombocytopenic purpura in Canada (Parenteral)